Pathogens and antimicrobial resistance in community-associated and healthcare-associated urinary tract infection
10.3969/j.issn.1671-9638.2015.09.009
- VernacularTitle:社区获得性与医院获得性泌尿道感染病原菌及耐药性
- Author:
Guangying HAN
;
Keji SHAN
;
Songting CHEN
;
Jianji YIN
;
Youyou MAO
;
Xin XIONG
- Publication Type:Journal Article
- Keywords:
urinary system infection;
healthcare-associated infection;
community-associated infection;
pathogen;
drug resistance,microbial
- From:
Chinese Journal of Infection Control
2015;(9):611-613,625
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the difference in constituent and antimicrobial resistance of pathogens in commu-nity-associated urinary tract infection(CA-UTI)and healthcare-associated UTI(HA-UTI).Methods Clinical data and microbial detection of urine specimens of 960 patients with UTI in a hospital between January 2013 and June 2014 were investigated retrospectively,difference in constituent and antimicrobial resistance of pathogens were ana-lyzed.Results 403 cases were CA-UTI,and 557 were HA-UTI;pathogens in both CA-UTI and HA-UTI were gram-negative bacteria,accounting for 78.16% and 66.97% respectively.Constituent of pathogens in CA-UTI and HA-UTI were significantly different(χ2 =21 .68,P <0.001 ).Resistant rates of Escherichia coli to piperacillin /tazobactam,cefazolin,cefoperazone / sulbactam,aztreonam,meropenem,ertapenem,gentamicin,and compound sulfamethoxazole were all significantly different between CA-UTI and HA-UTI (all P <0.05);Except aztreonam, resistant rates of Escherichia coli in HA-UTI to the other antimicrobial agents were all higher than CA-UTI.Re-sistant rates of Enterococcus faecium in HA-UTI to penicillin,ampicillin,gentamicin,levofloxacin,ciprofloxacin, and moxifloxacin were all higher than CA-UTI(all P <0.05).Conclusion Constituent and antimicrobial resistance of pathogens in CA-UTI and HA-UTI are different,proper antimicrobial agents should be chosen according to con-stituent features of pathogens and change in antimicrobial resistance,so as to prevent and reduce the emergence of drug-resistant strains,and improve therapeutic effectiveness.
